Cor Therapeutics Integrilin
Executive Summary
Promotional materials for eptifibatide injection fail "to present any risk information associated with Integrilin's use," FDA tells company in June 25 letter. The agency cited letters to physicians and pharmacists submitted by the company to the agency. Integrilin was approved in May for treatment of patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention ("The Pink Sheet" May 25, p. 11)